Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial

OBJECTIVE: Type 2 diabetes is a leading cause of kidney failure, but few outcome trials proactively enrolled individuals with chronic kidney disease (CKD). We performed secondary analyses of cardiovascular (CV) and kidney outcomes across baseline estimated glomerular filtration rate (eGFR) categorie...

Descripción completa

Detalles Bibliográficos
Autores principales: Perkovic, Vlado, Toto, Robert, Cooper, Mark E., Mann, Johannes F.E., Rosenstock, Julio, McGuire, Darren K., Kahn, Steven E., Marx, Nikolaus, Alexander, John H., Zinman, Bernard, Pfarr, Egon, Schnaidt, Sven, Meinicke, Thomas, von Eynatten, Maximillian, George, Jyothis T., Johansen, Odd Erik, Wanner, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2020
Materias:
Emerging Therapies: Drugs and Regimens
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7372065/
https://www.ncbi.nlm.nih.gov/pubmed/32444457
http://dx.doi.org/10.2337/dc20-0279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7372065/
https://www.ncbi.nlm.nih.gov/pubmed/32444457
http://dx.doi.org/10.2337/dc20-0279

Ejemplares similares